NCT06591481 (InnovaDetect) is a clinical trial in Axial Spondyloarthritis (AxSpA), sponsored by Ángel Alberich Bayarri.

Who is sponsoring NCT06591481?

NCT06591481 is sponsored by Ángel Alberich Bayarri.

What condition does NCT06591481 study?

NCT06591481 studies Axial Spondyloarthritis (AxSpA).

Is NCT06591481 still recruiting?

NCT06591481 is currently completed. Last updated 16 April 2025.

Last reviewed 2025-04-16 · How we verify

NCT06591481: InnovaDetect

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retrospective Case-Control Study for Developing an Artificial Intelligence (AI) Tool for Lesion Detection Using Magnetic Resonance Imaging (MRI) and Clinical Variables for Early Diagnosis of Axial Spondyloarthritis (axSpA)

Completed Last updated 16 April 2025

What this trial tests

trial in Axial Spondyloarthritis (AxSpA) in 925 participants. Completed in 3 April 2025.

Timeline

19 February 2023

Primary endpoint
3 April 2025

3 April 2025

Quick facts

Lead sponsor	Ángel Alberich Bayarri
Status	Completed
Study type	OBSERVATIONAL
Enrollment	925
Start date	19 February 2023
Primary completion	3 April 2025
Estimated completion	3 April 2025
Sites	7 locations across Jordan, Saudi Arabia, Spain, United Arab Emirates

Conditions studied

Axial Spondyloarthritis (AxSpA) — all drugs for Axial Spondyloarthritis (AxSpA) →

Sponsor

Ángel Alberich Bayarri

Who can join

Adults 18 to 44, any sex, with Axial Spondyloarthritis (AxSpA). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to develop and validate an Artificial Intelligence (AI) tool that allows the lesion detection and early diagnosis of axial spondyloarthritis (axSpA) based on Magnetic Resonance Imaging (MRI). This study will gather MRI scans from axSpA patients and a control group of participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Axial Spondyloarthritis (AxSpA)

Currently open trials in the same condition.

NCT07160231 — REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases · Phase 4 · recruiting
NCT07047703 — EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06591481 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ángel Alberich Bayarri
Last refreshed: 16 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06591481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing